(Q37514308)

20 August 2017

1 reference

title

Aptamers as inhibitors of target proteins (English)

1 reference

20 August 2017

S Missailidis

1

1 reference

20 August 2017

A Hardy

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

1073-1082

1 reference

Pegaptanib for the treatment of age-related macular degeneration

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

In vitro selection of RNA molecules that bind specific ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Technical and biological issues relevant to cell typing with aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Antiproliferative activity of G-rich oligonucleotides correlates with protein binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Discovery and development of anticancer aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Patents on SELEX and therapeutic aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

In vitro selection of RNA-based irreversible inhibitors of human neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Aptamer mediated siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Aptamer:toxin conjugates that specifically target prostate tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903042337

10.1517/13543770903042337

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference